Health Canada approves inhalation powder for COPD treatment

Stethoscope over the Canadian flag

A generic version of Spiriva, an inhalation powder for treating COPD, has been approved by Health Canada.

Lupin Pharma Canada Ltd., a subsidiary of global pharmaceutical company Lupin Limited, received the approval earlier this year. Tiotropium bromide inhalation powder is indicated in Canada for the long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with COPD. This also includes bronchitis and emphysema. It is not used for treating sudden breathing problems.

Sofia Mumtaz, MD, Lupin president of legal for Canada, Australia and Japan, said this is a big step forward in the affordable treatment of COPD.

“This approval of the first generic for Tiotropium bromide inhalation powder by Health Canada underscores our commitment to bring affordable options of complex products for patients in Canada, particularly in the respiratory therapeutic area,” she said.

Lupin is based in Mumbai, India, and develops and commercializes branded and generic formulations, biotechnology products and APIs in more than 100 markets, including the Europe, India, Latin America, the Middle East, South Africa and the United States.

More in COPD
Page 1 of 13
Next Page